At last, a vaccine has been developed and licensed that could help eliminate the deadly disease meningitis B, which in bacterial form kills 200 people a year in Britain.
Unfortunately, the cost "could prevent its being made swiftly available through the national vaccination programme," according to a recent newspaper article.
One wonders how much profit the shareholders of manufacturers Novartis will be demanding to save so many lives?
How much will the government be prepared to pay?
If we can afford billions to upgrade the strategically useless Trident weapons system, which won't save a single life, we should be able to afford Novartis's blood money.
There's no problem for the rich, however, as the vaccine will be available to buy privately as soon as it's launched.
There is something very, very wrong about a society which collectively educates scientists to develop such wonderful products, which are then immediately available only to a rich minority.
If you appreciated this article then please consider donating to the Morning Star's Fighting Fund to ensure we can keep developing your paper.
Donate to the Fighting Fund here